Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L Bakris, Melanie Chin, Heidi Christ-Schmidt, Angie Goldsberry, Mark Houser, Melissa Krauth, Hiddo J Lambers Heerspink, John J McMurray, Colin J Meyer, Hans-Henrik Parving, Giuseppe Remuzzi, Robert D Toto, Nosratola D Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Glenn M ChertowBEACON Trial Investigators

    821 Citations (Scopus)


    Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown.
    Original languageEnglish
    JournalThe New England journal of medicine
    Issue number26
    Pages (from-to)2492-503
    Number of pages12
    Publication statusPublished - 26 Dec 2013


    Dive into the research topics of 'Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease'. Together they form a unique fingerprint.

    Cite this